COVID-19 vaccine deployment expected in UK till new year: report

The first vaccine is to be given to the elderly and vulnerable. (Representative)

London:

According to a media report on Sunday, one of the UK’s most senior medical chiefs has indicated that a vaccine against COVID-19 may be ready to be deployed by the start of the new year.

Jonathan Van-Tam, England’s deputy chief medical officer and one of the government’s advisors on the coronovirus epidemic, has reportedly told members of parliament (MPs) that the vaccine, made at the University of Oxford and produced by Astraseneca, would rollout soon after Christmas. Can be prepared for. In December.

In India, the vaccine has a serum Institute of India tie-up as it undergoes testing.

“The Sunday Times” quoted Van Tam as writing, “We are not far from it. It is not entirely unrealistic to suggest that we may deploy a vaccine immediately after Christmas. This has greatly reduced hospital admissions and deaths.” Will affect. Tell MPs during a briefing last week.

An MP who attended another briefing with Van-Tam told the newspaper that the drug was “very sharp about the results of the third-phase AstraZeneca, which they expect between the end of this month and the end of next”.

The MP said, “Van-Tam expects to protect the elderly and vulnerable. He has given us to understand that this will stop the flow of virus among the youth. He said that he would expect vaccination in January.” . “

This comes as the UK government on Friday introduced new laws that would allow a large number of health workers to operate the flu and potentially COVID-19 vaccines.

“COVID-19 vaccines are being developed rapidly, which will save people’s lives if they are successful,” Van-Tam quoted the new regulations.

“All vaccines must go through three stages of clinical trials and be evaluated by the regulator for safety and effectiveness before they are given to patients. The stated measures are intended to improve existing safeguards and protect existing patients who are safeguarded. The measures have to be strengthened. “

The Department of Health and Social Care (DHSC) said the new measures would increase access to vaccines against potentially killer diseases, as well as support the government’s plans for a roll-out of a potential COVID-19 vaccine that would prove to be safe and effective Is approved through strong clinical trials and for use by the regulator.

Britain’s Health Secretary Matt Bangkok said, “Every year millions of people in the National Health Service (NHS) have extensive experience of disease prevention.”

“These legal changes will help us do all that we can to ensure that we are ready to produce a safe and effective COVID-19 vaccine, as soon as it is ready for clinical trials and Has undergone rigorous scrutiny by the regulator, ”.

It aims to increase the number of fully trained and experienced healthcare professionals to operate COVID-19 and flu vaccines under the NHS and local authority occupational health plans, as well as to enable an expanded workforce that To make these vaccinations public. The DHSC said this would make it easier and quicker for patients and health workers to access the vaccines needed to prevent fatal diseases.

Therefore, if a vaccine is developed before 2021, the change in human medicine regulations will increase existing powers to authorize the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) to provide temporary supplies for any treatment or vaccine Which enables one to respond to public health needs.

This means that if a vaccine is found to meet safety, quality and effectiveness standards by the MHRA, vaccination can begin without waiting for the European Medicines Agency, which ends the infection period on 31 December this year Till then. – There would be only one body capable of granting licenses.

The Interim Chief Scientific Officer at MHRA, Drs. Christian Schneider said: “No vaccine will be deployed until stringent standards have been met through an extensive clinical trial program.

“The preferred route to enable the deployment of any new vaccine remains through normal product licensing processes. But our ability to strengthen regulatory governance and protect public health now requires reinforced security measures, temporary. Authorization should be necessary. “

Vaccines are first given to the elderly and vulnerable, followed by vaccinations to those at highest risk. Any population-wide roll-out is expected to be a very long-term process.

(This story is not edited by NDTV staff and auto-generated from a syndicated feed.)

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *